KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Shares Outstanding (Weighted Average) (2016 - 2025)

Biogen (BIIB) has 17 years of Shares Outstanding (Weighted Average) data on record, last reported at $146.5 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 0.62% year-over-year to $146.5 million; the TTM value through Dec 2025 reached $146.5 million, up 0.62%, while the annual FY2025 figure was $146.5 million, 0.62% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $146.5 million in Q4 2025 per BIIB's latest filing, roughly flat from $146.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $151.9 million in Q1 2021 and bottomed at $144.4 million in Q3 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $146.4 million, with a median of $145.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): dropped 12.09% in 2021, then grew 0.62% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $149.1 million in 2021, then decreased by 2.55% to $145.3 million in 2022, then decreased by 0.41% to $144.7 million in 2023, then increased by 0.62% to $145.6 million in 2024, then grew by 0.62% to $146.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $146.5 million in Q4 2025, $146.4 million in Q3 2025, and $146.3 million in Q2 2025.